Table 1 Patient characteristics at time of first orlistat prescription during the follow up period (1st Jan 2006 -30th Nov 2009)
| Â | Orlistat population | Male | Female |
|---|---|---|---|
(N = 79) | (N = 15) | (N = 64) | |
| Â | (19% of total) | (81% of total) | |
Age n (%) | |||
Children (under 17Â years) | 24 (30.5%) | 4 (26.7%) | 20 (31.3%) |
Young people (17 – 18 years) | 55 (69.6%) | 11 (73.3%) | 44 (68.7%) |
Median (IQR) | 17 (16–18) | ||
BMI SDS n (%) | |||
<2.5 | 12 (15.2%) | 0 | 12 (18.8%) |
2.5 – 3.49 | 24 (30.4%) | 6 (40%) | 18 (28.1%) |
>3.5 | 18 (22.8%) | 6 (40%) | 12 (18.8%) |
Missing | 25 (31.6%) | 3 (20%) | 22 (34.4%) |
Mean (SD) | 3.13 (1.0) | ||
Deprivation SIMD (2006) n (%) | |||
1-2 (least deprived) | 8 (10.1%) | 1 (6.7%) | 7 (10.9%) |
3-4 | 7 (8.9%) | 2 (13.3%) | 5 (7.8%) |
5-6 | 20 (25.3%) | 3 (20.0%) | 17 (26.6%) |
7-8 | 18 (22.8%) | 7 (46.7%) | 11 (17.2%) |
9-10 (most deprived) | 26 (32.9%)* | 2 (13.3%) | 24 (37.5%) |
Co-prescribed drug classes n (%) | |||
0 | 24 (30.4%) | 7 (46.7%) | 17 (26.6%) |
1-4 | 52 (65.8%) | 8 (53.3%) | 44 (68.8%) |
>4 | 3 (3.8%) | 0 (0.0%) | 3 (4.7%) |
Median (IQR) | 1 (0–2) | ||